Status:
RECRUITING
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study
Lead Sponsor:
Children's Hospital of Philadelphia
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
ADPKD
Eligibility:
All Genders
Up to 18 years
Brief Summary
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of renal failure. For several decades, ADPKD was regarded as an adult-onset disease. In the last decade, it has be...
Detailed Description
This study will ask the subject's permission to see past, current, and future medical information related to the disease. Some information that is collected, would be clinic notes, lab results, and ph...
Eligibility Criteria
Inclusion
- Demonstration of ADPKD by clinical information, imaging studies, biopsy, autopsy, or genetic testing.
Exclusion
- Patients with Autosomal Recessive Polycystic Kidney disease (ARPKD), urinary tract malformations or major congenital anomalies of other systems suggesting a diagnosis other than recessive hepato-renal fibrocystic diseases.
Key Trial Info
Start Date :
October 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 30 2030
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04338048
Start Date
October 10 2019
End Date
October 30 2030
Last Update
June 13 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's National Hospital
Washington D.C., District of Columbia, United States, 20010
2
Mayo Clinic
Rochester, Minnesota, United States, 55902
3
Cohen Children's Medical Center
New Hyde Park, New York, United States, 11042
4
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19146